Company

Milestone Pharmaceuticals Inc.

Headquarters: Montreal, QC, Canada

Employees: 28

CEO: Mr. Joseph G. Oliveto

NASDAQ: MIST -1.38%

Market Cap

$103.7 Million

USD as of July 1, 2025

Market Cap History

Milestone Pharmaceuticals Inc. market capitalization over time

Evolution of Milestone Pharmaceuticals Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Milestone Pharmaceuticals Inc.

Detailed Description

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. It is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as in the Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate, and other cardiovascular indications. Milestone Pharmaceuticals Inc. has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil in patients with paroxysmal supraventricular tachycardia and additional cardiovascular conditions in Greater China. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

Stocks & Indices

Milestone Pharmaceuticals Inc. has the following listings and related stock indices.


Stock: NASDAQ: MIST wb_incandescent

Details

Headquarters:

1111 Dr. Frederik-Philips Boulevard

Suite 420

Montreal, QC H4M 2X6

Canada

Phone: 514 336 0444